Cargando…
Fulminant Cardiotoxicity in a Patient With Cardiac Lymphoma Treated With CAR-T Cells
[Figure: see text]
Autores principales: | Koch, Christian, Montrasio, Giulia, Scherr, Benedikt Florian, Schimmer, Roman, Matter, Christian M., Bühler, Karl Philipp, Manz, Markus G., Müller, Antonia M.S. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9830210/ https://www.ncbi.nlm.nih.gov/pubmed/36636430 http://dx.doi.org/10.1016/j.jaccao.2022.07.012 |
Ejemplares similares
-
CardioMEMS-Guided CAR T Cell Therapy for Lymphoma in a Patient With Anthracycline-Induced Cardiomyopathy
por: Kanelidis, Anthony J., et al.
Publicado: (2020) -
Immune-Checkpoint Inhibitor-Induced Fulminant Myocarditis and Cardiogenic Shock
por: Itzhaki Ben Zadok, Osnat, et al.
Publicado: (2019) -
Delayed Diagnosis and Recovery of Fulminant Immune Checkpoint Inhibitor-Associated Myocarditis on VA-ECMO Support
por: Ramayya, Tarun, et al.
Publicado: (2022) -
Uridine Triacetate for Severe Fluoropyrimidine Cardiotoxicity in a Patient With Thymidylate Synthase Gene Variants
por: Raber, Inbar, et al.
Publicado: (2020) -
Successful CAR T Cell Therapy in a Heart and Kidney Transplant Recipient With Refractory PTLD
por: Oren, Daniel, et al.
Publicado: (2022)